ALLO - FDA clears Allogene Therapeutics' ALLO-605 application in multiple myeloma

The FDA has cleared an Investigational New Drug ((IND)) application of Allogene Therapeutics (ALLO) to study ALLO-605 for the treatment of patients with relapsed or refractory multiple myeloma.ALLO-605 is part of the company’s multi-faceted strategy to develop an allogeneic CAR T therapy targeting BCMA for the treatment of multiple myeloma.The Phase I IGNITE trial will evaluate escalating doses of ALLO-605 beginning in mid-2021. ALLO-605 incorporates Allogene’s TurboCAR technology, which allows for cytokine activation signaling to be engineered selectively into CAR T cells.

For further details see:

FDA clears Allogene Therapeutics' ALLO-605 application in multiple myeloma